2026-07-02 · opioids, chronic pain, long-term opioid therapy, opioid-induced hypogonadism, weight gain, weight loss · 18 min read

Will oxycodone make me gain weight?

In the short term, most of the weight signal from oxycodone or hydrocodone is constipation-driven — Camilleri 2017 in Nature Reviews Gastroenterology and Hepatology and Argoff 2015 in the Mayo Clinic Proceedings both report opioid-induced constipation in 40 to 60 percent of long-term opioid users, and the resulting bloating and food-avoidance patterns show up on the scale in unpredictable ways over the first weeks. Over months to years the picture shifts. Long-term opioid therapy drives opioid-induced hypogonadism in roughly 50 to 75 percent of chronic users (Fraser 2009 Clinical Endocrinology; Vuong 2010 Endocrine Reviews), which lowers testosterone and estradiol, drops lean mass, and produces a sarcopenic body-composition shift that is not obvious on the scale but matters for function. Pain-driven activity reduction is usually the biggest single lever. None of this justifies stopping oxycodone on your own — sudden opioid discontinuation is dangerous per the CDC 2022 Clinical Practice Guideline. Bring the weight question to the prescribing clinician.

Why did I gain 20 pounds on methadone?

This is one of the most consistent weight signals in all of pain and addiction medicine, and it is not a personal failure. Dursteler 2014 in Drug and Alcohol Dependence documented mean weight gain of 5 to 15 kg in the first year of methadone maintenance for opioid use disorder, and Ferrari 2012 in Current Medical Research and Opinion reviewed the mechanism — a combination of appetite normalisation after the pre-treatment pattern of stimulant, alcohol, or under-eating that often accompanies untreated OUD, direct opioid-receptor effects on satiety and reward, craving displacement toward food, and methadone's long half-life sustaining these effects around the clock. The critical framing from SAMHSA 2023 is that methadone dose reduction is not the answer to methadone weight gain — dose reduction risks OUD relapse and overdose. The answer is behavioural, dietary, and activity work on top of a therapeutic maintenance dose, in coordination with the OUD care team. Call SAMHSA at 1-800-662-HELP for treatment resources.

Can I take Ozempic or Wegovy on opioids?

Yes for most patients, but with two specific caveats and always with prescriber coordination. First, both semaglutide and opioids slow gastrointestinal transit, so the constipation risk is additive — Camilleri 2017 in Nature Reviews Gastroenterology and Hepatology and Argoff 2015 in the Mayo Clinic Proceedings frame opioid-induced constipation as the most predictable opioid GI effect, and layering a GLP-1 on top typically requires an osmotic laxative and sometimes a PAMORA such as methylnaltrexone or naloxegol. Second, opioids and GLP-1 nausea can be additively sedating and reduce appetite to the point of inadequate protein and calorie intake, which is not the goal. The Wilding 2021 STEP-1 trial and the Jastreboff 2022 SURMOUNT-1 trial did not exclude opioid users, but coordinating both prescribers is important. Naltrexone-bupropion (Contrave) is a different question — it is contraindicated in anyone taking any opioid because naltrexone is an opioid antagonist and can precipitate withdrawal.

Will tapering opioids help me lose weight?

Often yes, but the mechanism is indirect. The Krebs 2018 SPACE trial in JAMA compared opioid and non-opioid regimens for chronic low back pain and knee or hip osteoarthritis and found opioids were not superior for pain-related function over 12 months, and the Ballantyne 2003 New England Journal of Medicine review of opioid tolerance and hyperalgesia framed the same finding pharmacologically — long-term opioids modestly reduce pain intensity without reliably restoring function. When a supervised taper works, what typically improves is sleep, morning alertness, activity tolerance, and appetite regulation, and those changes drive weight change more than any direct metabolic opioid effect. The critical rule from the CDC 2022 Clinical Practice Guideline is never self-taper. Sudden opioid discontinuation is dangerous — precipitating withdrawal, uncontrolled pain, and increased overdose risk if opioids are resumed at prior doses. Any taper is a prescriber-supervised process.

Is opioid-induced low testosterone real?

Yes, and it is one of the best-characterised endocrine effects of long-term opioid therapy. Fraser 2009 in Clinical Endocrinology reported opioid-induced hypogonadism in 50 to 75 percent of long-term opioid users, Vuong 2010 in Endocrine Reviews summarised the comprehensive endocrine picture (testosterone, LH, FSH suppression, altered cortisol and DHEA-S, occasional adrenal insufficiency), and Grey 2011 in the Journal of Clinical Endocrinology and Metabolism mapped the hypothalamic-pituitary-gonadal and hypothalamic-pituitary-adrenal axes. The clinical picture is fatigue, low libido, erectile dysfunction, low mood, and lean-mass loss over months to years. The workup is a morning total testosterone (with free testosterone if borderline), LH, FSH, and prolactin, and Rhodin 2010 in the European Journal of Pain reported functional improvement with testosterone replacement in appropriately screened opioid-treated men. Women get parallel changes in estradiol and menstrual regularity that warrant the same specialty conversation.

Can I use Contrave (naltrexone-bupropion) on opioids?

No — this is one of the clearest contraindications in weight-loss medication. Naltrexone is an opioid antagonist, and giving it to a patient on any opioid analgesic or on medications for opioid use disorder (MOUD) such as methadone or buprenorphine can precipitate abrupt, severe withdrawal — nausea, vomiting, sweating, agitation, and in some cases hypertensive urgency. This includes not just prescription opioids like oxycodone, hydrocodone, morphine, and fentanyl but also tramadol, tapentadol, and codeine. The FDA label for Contrave is explicit. If you are on any opioid, the weight-loss medication options are GLP-1 agonists (semaglutide, liraglutide, tirzepatide) with prescriber coordination, phentermine or phentermine-topiramate in appropriate candidates, or non-medication behavioural approaches. See our weight-loss drug safety guide for the full contraindication list.

Does buprenorphine cause less weight gain than methadone?

Yes — this is one of the more consistent findings in the MOUD literature. Dursteler 2014 in Drug and Alcohol Dependence directly compared methadone and buprenorphine maintenance and reported meaningfully less weight gain on buprenorphine, and the Wardhan 2017 F1000Research review summarised the buprenorphine advantage. The likely mechanism is buprenorphine's partial-agonist pharmacology at the mu-opioid receptor — the same feature that gives it a ceiling on respiratory depression also appears to blunt the appetite and satiety effects that drive methadone weight gain. The trade-off is that buprenorphine is not the right medication for every patient — methadone remains first-line for many higher-severity or higher-dose OUD situations, and switching medications for weight reasons alone is rarely appropriate. This is a conversation with the OUD care team, not a self-directed swap. SAMHSA 2023 covers the full MOUD framework.

Do opioids cause bone loss and fracture risk?

Yes, and this is often overlooked in the weight conversation. Vestergaard 2006 in the Journal of Internal Medicine documented reduced bone mineral density and elevated fracture risk in long-term opioid users, driven partly by opioid-induced hypogonadism (low testosterone or estradiol reduces bone turnover) and partly by reduced weight-bearing activity from pain-driven de-conditioning. The Debono 2011 Journal of Clinical Endocrinology and Metabolism report on opioid-induced adrenal insufficiency adds another layer for a subset of chronic users. Practical steps: baseline DEXA in long-term users, calcium 1,000 to 1,200 mg and vitamin D 800 to 1,000 IU per day, resistance training within the pain envelope, fall-risk assessment, and testosterone replacement in confirmed hypogonadism where clinically appropriate. See our osteoporosis and weight loss and low testosterone and weight loss guides.

Opioids and Weight Changes: Chronic Pain, Long-Term Use, and What Helps

Quick stats

• US adults on long-term opioid therapy in 2026: ~10 million (CDC 2022 MMWR Recomm Rep)
• Opioid-induced hypogonadism prevalence in long-term users: ~50–75% (Fraser 2009 Clin Endocrinol)
• Opioid-induced constipation prevalence: ~40–60% (Camilleri 2017 Nat Rev Gastroenterol Hepatol; Argoff 2015 Mayo Clin Proc)
• Mean weight gain on methadone maintenance in first year: 5–15 kg (Dursteler 2014 Drug Alcohol Depend; Ferrari 2012 Curr Med Res Opin)
• 988 Suicide & Crisis Lifeline: call or text 988 (US). SAMHSA National Helpline: 1-800-662-HELP (4357) for OUD treatment

The honest picture, in one paragraph

Direct opioid effects on scale weight are heterogeneous and often modest in short-term use, but three linked mechanisms make long-term opioid therapy weight-relevant. Opioid-induced hypogonadism — Fraser 2009 (Clinical Endocrinology) and Vuong 2010 (Endocrine Reviews) both put the prevalence at 50–75% in chronic users — lowers testosterone and estradiol and produces lean-mass loss and a sarcopenic body-composition shift. Pain-driven de-conditioning and activity restriction — the biggest single lever in most chronic pain populations — reduces energy expenditure and worsens function without necessarily changing the scale. And medications for opioid use disorder (MOUD), especially methadone, drive reliable weight gain of 5–15 kg in the first year of maintenance (Dursteler 2014 Drug and Alcohol Dependence; Ferrari 2012 Current Medical Research and Opinion). The Krebs 2018 SPACE trial in JAMA is the anchor for the broader question: over 12 months of chronic non-cancer pain treatment, opioids did not outperform non-opioid analgesics for pain-related function. The CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Pain and Dowell 2022 JAMA commentary frame the modern prescribing standard, and the Chou 2015 AHRQ evidence review and Volkow 2021 New England Journal of Medicine piece anchor the long-term efficacy and public-health context. Any change to opioid therapy — dose, taper, switch, or discontinuation — is a conversation with the prescribing clinician. Never self-taper.

How opioid categories differ for weight

The opioid class covers pharmacologically distinct medications used for very different indications — acute post-surgical pain, chronic non-cancer pain, cancer pain, and opioid use disorder. Each subclass produces a distinct weight signal.

If your prescribing picture involves additional pain-adjunct medications — SNRIs, gabapentinoids, or antipsychotics — the layered weight effect can be substantial. See antidepressants and weight changes for the SNRI side, and corticosteroids and weight gain for common flare-management overlaps.

Why long-term opioids change weight — 4 drivers

The mechanism is not a single pathway. Four drivers stack, and each one shows up at a different point in a chronic-therapy course.

1. Opioid-induced hypogonadism (OIH-endocrine)

Fraser 2009 (Clinical Endocrinology) documented opioid-induced hypogonadism in 50–75% of long-term opioid users, and Vuong 2010 (Endocrine Reviews) mapped the full endocrine picture — suppression of hypothalamic gonadotropin-releasing hormone, downstream drops in LH, FSH, testosterone, and estradiol, occasional elevations in prolactin, and altered adrenal axis function. Grey 2011 (Journal of Clinical Endocrinology and Metabolism) added the parallel HPA-axis findings and Debono 2011 (Journal of Clinical Endocrinology and Metabolism) described opioid-induced adrenal insufficiency in a subset of chronic users. The clinical picture is fatigue, low libido, low mood, and — critical for body composition — loss of lean mass, sarcopenic muscle change, and reduced exercise capacity. Screening is a morning total testosterone (with free testosterone if borderline), LH, FSH, and prolactin; women get parallel estradiol and cycle history. Rhodin 2010 (European Journal of Pain) supports testosterone replacement in appropriately screened opioid-treated men. See low testosterone and weight loss and cortisol, stress, and weight gain.

2. Opioid-induced constipation and gut motility change

Camilleri 2017 (Nature Reviews Gastroenterology and Hepatology) and Argoff 2015 (Mayo Clinic Proceedings) both put opioid-induced constipation prevalence at 40–60% in long-term users. Unlike many opioid side effects, constipation does not reliably diminish with tolerance — mu-opioid receptors in the enteric nervous system stay engaged for the duration of therapy. The downstream weight effects are indirect but real: bloating and abdominal discomfort drive some patients to under-eat, others to over-treat with laxatives that produce their own dysfunction, and both patterns disrupt the regular meal timing that supports appetite regulation. See constipation during weight loss for the general management framework; the opioid-specific answer often requires an osmotic laxative first and a peripherally-acting mu-opioid receptor antagonist (PAMORA) — methylnaltrexone or naloxegol — for refractory cases per Argoff 2015.

3. Pain-driven activity reduction and sleep fragmentation

Katz 2011 (Pain) mapped the dose-function relationship on chronic opioid therapy and showed that dose escalation modestly reduces pain intensity without reliably restoring physical function — the classic uncoupling of pain relief from activity. Krebs 2018 (JAMA) — the SPACE trial — is the strongest evidence base for the practical implication: over 12 months of chronic non-cancer pain treatment, opioids did not outperform non-opioid analgesics for pain-related function. The weight implication is that de-conditioning, sleep fragmentation from unresolved pain, and the resulting cascade of low activity, low energy expenditure, and disrupted appetite regulation are the biggest levers most chronic-pain patients can pull. See back pain and weight loss, fibromyalgia and weight loss, sleep, stress, and weight management, and strength training for weight loss.

4. MOUD-specific weight gain (methadone > buprenorphine)

The biggest single opioid weight signal in the literature is methadone maintenance for opioid use disorder. Dursteler 2014 (Drug and Alcohol Dependence) reported mean weight gain of 5–15 kg in the first year of methadone maintenance, and Ferrari 2012 (Current Medical Research and Opinion) reviewed the proposed mechanisms — appetite normalisation after the pre-treatment pattern of stimulant, alcohol, or under-eating that often accompanies untreated OUD; direct opioid-receptor effects on satiety and reward pathways; craving displacement toward food, particularly sweets; and methadone’s long half-life sustaining these effects continuously rather than in the peak-trough pattern of shorter-acting opioids. Wardhan 2017 (F1000Research) documented meaningfully less weight gain on buprenorphine maintenance — Suboxone, Zubsolv, Sublocade — likely because the partial-agonist pharmacology that gives buprenorphine its safety ceiling also blunts the satiety and reward effects. The SAMHSA 2023 MAT guideline is unambiguous: methadone dose reduction is not the answer to methadone weight gain, because dose reduction risks OUD relapse and overdose. The answer is behavioural, dietary, and activity work layered on top of therapeutic maintenance.

Dose, MME, and cumulative-exposure effect

Chronic opioid therapy is typically quantified in morphine milligram equivalents (MME) per day, which allows dose-response comparisons across compounds. The CDC 2022 guideline treats ≥50 MME/day as a threshold for elevated overdose risk requiring careful documentation of benefits vs harms, and ≥90 MME/day as the threshold that generally warrants specialty consultation. The table below is the honest lookup for the weight-related endpoints.

Vestergaard 2006 (Journal of Internal Medicine) is the anchor for the osteoporosis and fracture-risk piece — driven partly by hypogonadism-related bone loss and partly by pain-driven inactivity — and the practical implication is a low threshold for baseline and follow-up DEXA imaging in long-term users. Häuser 2020 (IASP position on opioids for chronic non-cancer pain) and APS/AAPM 2009 frame the dose-time thresholds for structured re-evaluation, and Katz 2011 (Pain) covers the dose-function trajectory.

5-step opioid-and-weight protocol

Always coordinated with the prescribing clinician. Never self-taper.

Step 1: Confirm the indication and coordinate with your prescriber

Sudden opioid discontinuation is dangerous — precipitating acute withdrawal, uncontrolled pain, and, if opioids are resumed at prior doses after even a brief interruption, meaningfully elevated overdose risk. CDC 2022 and Dowell 2022 (JAMA) are both explicit: any change is a conversation, not a self-directed cut. The first step is a documented picture of the current regimen — drug, dose in MME/day, duration, indication, other pain-adjunct medications, and the goals of therapy. See weight-loss drug safety for the broader medication-review framework.

Step 2: Treat constipation actively

Osmotic laxatives (polyethylene glycol, lactulose) are the first-line approach for opioid-induced constipation per Argoff 2015 (Mayo Clinic Proceedings) and Camilleri 2017 (Nature Reviews Gastroenterology and Hepatology). Fibre and hydration help but rarely resolve the problem alone. Refractory cases warrant a peripherally-acting mu-opioid receptor antagonist (PAMORA) — methylnaltrexone or naloxegol — which reverses the peripheral opioid effect on gut motility without affecting central analgesia. See constipation during weight loss.

Step 3: Screen and treat opioid-induced hypogonadism

A morning total testosterone (with free testosterone if borderline), LH, FSH, and prolactin is the standard workup for men on long-term opioids per Fraser 2009 (Clinical Endocrinology) and Vuong 2010 (Endocrine Reviews). Women get parallel estradiol, LH, FSH, and cycle history. Rhodin 2010 (European Journal of Pain) supports testosterone replacement in appropriately screened opioid-treated men with symptomatic hypogonadism, and a subset of chronic users warrants ACTH-stimulation testing for opioid-induced adrenal insufficiency per Debono 2011 (Journal of Clinical Endocrinology and Metabolism). See low testosterone and weight loss.

Step 4: Rebuild activity within the pain envelope

This is the single biggest lever in most chronic-pain populations. Graded exposure, physical therapy, aquatic exercise, and resistance training within clinician-approved limits address the de-conditioning driver directly. Katz 2011 (Pain) and Krebs 2018 (JAMA) both point to function — not pain intensity — as the endpoint that matters most for long-term outcomes. See strength training for weight loss, back pain and weight loss, and fibromyalgia and weight loss.

Step 5: Optimise non-opioid analgesia and behavioural pain management

Krebs 2018 (JAMA) — the SPACE trial — is the strongest evidence base for non-opioid analgesic optimisation in chronic non-cancer pain. Acetaminophen, NSAIDs where safe, topical agents, SNRIs (duloxetine) or gabapentinoids for neuropathic components, and structured cognitive-behavioural therapy for chronic pain (CBT-CP) all have real evidence bases. When these are optimised, some patients and their prescribers agree on a supervised opioid dose reduction; that is a shared decision, not a self-directed one. See sleep, stress, and weight management and cortisol, stress, and weight gain.

What treatments actually do — comparison

Special situations

Methadone maintenance and weight

The methadone-maintenance weight signal is the largest and most consistent in the entire MOUD literature. Dursteler 2014 (Drug and Alcohol Dependence) reports 5–15 kg mean gain in the first year, and Ferrari 2012 (Current Medical Research and Opinion) reviews the mechanistic hypotheses. The single most important framing — from SAMHSA 2023 — is that methadone dose reduction is not the answer to methadone weight gain. Dose reduction risks OUD relapse and overdose, and both are far more dangerous than 10 kg of weight gain in a maintenance patient. The right answer is layered: consistent meal timing (3 meals plus a planned snack), 1.0–1.2 g/kg protein per day distributed across those meals, an activity anchor (7,000–10,000 steps or an equivalent aquatic or resistance program), sleep-first sequencing (7–9 hours), and structured behavioural support. GLP-1 medications are increasingly considered in maintenance patients with BMI in the medication range and no contraindications, and should be coordinated with the OUD care team. Contrave (naltrexone-bupropion) is contraindicated — the naltrexone component will precipitate withdrawal.

Buprenorphine (Suboxone, Zubsolv, Sublocade) and weight

Buprenorphine — as analgesic (Belbuca, Butrans) or as MOUD (Suboxone sublingual film, Zubsolv sublingual tablet, Sublocade monthly injection) — produces a smaller and less predictable weight signal than methadone per Wardhan 2017 (F1000Research) and the SAMHSA 2023 framework. The pharmacology is partial mu-opioid agonism with a ceiling on respiratory depression, and that ceiling appears to blunt the satiety and reward effects that drive methadone weight gain. In many contexts buprenorphine is the safer analgesic and MOUD choice, but this is not a reason to switch medications for weight alone — the OUD care team makes that decision with the patient based on severity, prior response, and treatment goals.

Opioid taper and weight

Krebs 2018 SPACE and Ballantyne 2003 (New England Journal of Medicine) both frame the same finding: long-term opioids modestly reduce pain intensity without reliably restoring function, and supervised taper in appropriately selected patients often produces improvements in sleep, morning alertness, activity tolerance, and mood. Some patients see a small weight change as appetite regulation and activity return; others see none. The critical rule is that any taper is prescriber-supervised — CDC 2022 and Dowell 2022 (JAMA) both make this explicit. Rapid or forced tapers have been associated with worse outcomes including relapse and self-harm; shared-decision, gradual tapers are the standard. If you are having thoughts of self-harm at any point, call or text 988.

Cancer pain — different rules

Cancer pain opioid use is exempted from the CDC 2022 chronic-non-cancer-pain recommendations. Cancer-pain regimens are guided by oncology and palliative-care teams, dose escalation is often clinically appropriate, and weight goals are individualised — typically not deficit-oriented during active disease, and often centred on preserving lean mass and nutritional status. See cancer and weight loss and breast cancer survivor weight for the survivorship and adjuvant-therapy pictures.

OUD and weight-loss medication safety

The single most important rule in this section: Contrave (naltrexone-bupropion) is contraindicated in anyone taking any opioid — analgesic, MOUD, or otherwise — because the naltrexone component is a full opioid antagonist and can precipitate abrupt, severe withdrawal. This includes methadone, buprenorphine, oxycodone, hydrocodone, morphine, fentanyl, tramadol, tapentadol, and codeine. GLP-1 medications (semaglutide, liraglutide, tirzepatide) are not contraindicated on opioids but layer additive constipation and, in some patients, additive sedation; coordinate prescribers. Phentermine and phentermine-topiramate are options in appropriate candidates. See weight-loss drug safety for the full contraindication list.

Osteoporosis and fracture risk

Vestergaard 2006 (Journal of Internal Medicine) established the elevated fracture and reduced bone-mineral-density signal in long-term opioid users, driven by opioid-induced hypogonadism (low testosterone and estradiol reduce bone remodelling) and by pain-driven inactivity that reduces weight-bearing stimulus. Practical steps: baseline DEXA in long-term users, calcium 1,000–1,200 mg and vitamin D 800–1,000 IU per day, resistance training within the pain envelope, fall-risk assessment (especially in methadone patients given QT and sedation considerations), and testosterone replacement in confirmed hypogonadism where clinically appropriate.

Red flags — when to call a doctor

If you are having thoughts of self-harm or suicide, call or text 988 (Suicide & Crisis Lifeline) right now. For opioid use disorder treatment resources, call the SAMHSA National Helpline at 1-800-662-HELP (4357) — free, confidential, 24/7.

• Respiratory depression, unusual sleepiness, pinpoint pupils, or witnessed overdose — call 911, use naloxone (Narcan, Kloxxado) if available. Everyone on chronic opioids or MOUD should have naloxone at home per CDC 2022.
• Suspected diversion, misuse, or loss of control over opioid use — this is not a moral failure; it is a treatable medical condition. Call 1-800-662-HELP or ask your prescriber for a MOUD referral.
• Symptoms of adrenal-insufficiency crisis — severe fatigue, low blood pressure, nausea, vomiting, abdominal pain — in a long-term opioid user; same-day evaluation per Debono 2011.
• Sudden unintentional weight loss in a chronic-pain patient — do not attribute to opioids alone; evaluate for cancer, thyroid disease, malabsorption, or worsening underlying condition.
• Uncontrolled constipation with abdominal distension, severe pain, vomiting, or no bowel movement for more than 3–4 days — evaluate for bowel obstruction, especially in higher-dose users.
• New or worsening depression, anxiety, or suicidal ideation on chronic opioids or during a taper — call 988 and reach the prescribing clinician the same day.

Opioids and Weight Changes FAQ

Will oxycodone make me gain weight? Short-term signal is mostly constipation-driven; long-term signal is endocrine (opioid-induced hypogonadism) plus de-conditioning.

Why did I gain 20 pounds on methadone? Methadone maintenance reliably drives 5–15 kg gain in year one (Dursteler 2014); dose reduction is not the answer per SAMHSA 2023.

Can I take Ozempic on opioids? Yes with prescriber coordination; expect additive constipation and sometimes additive sedation.

Will tapering opioids help me lose weight? Often indirectly — via better sleep, activity, and appetite regulation — but never self-taper.

Is opioid-induced low testosterone real? Yes — 50–75% prevalence in long-term users (Fraser 2009); check a morning testosterone.

Can I use Contrave (naltrexone-bupropion)? No — contraindicated in anyone on any opioid or MOUD.

Does buprenorphine cause less weight gain than methadone? Yes — meaningfully less per Dursteler 2014 and Wardhan 2017.

Do opioids cause bone loss and fracture risk? Yes — Vestergaard 2006; baseline DEXA and calcium/vitamin D are the anchors.